Navigation Links
NeoStem Announces Participation in Multiple October Conferences
Date:10/4/2011

the manufacture and distribution of living, licensed products for the healthcare community."  

About NeoStem, Inc.

NeoStem is a leader in the development and manufacturing of cell therapies. The Company's strategic combination of revenues with manufacturing through its subsidiary, Progenitor Cell Therapy, LLC and global reach has positioned the company for breakthroughs in the cell therapy industry. The acquisition of Amorcyte, Inc. (which is expected to close in the fourth quarter subject to shareholder approval) will position NeoStem to achieve its mission of capturing the paradigm shift to cell therapy. NeoStem is also pursuing a T-cell therapeutic with potential in a range of auto-immune conditions and development of its VSEL™ Technology platform. For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's successful development of cell therapeutics, as well as the future of the cell therapeutics industry. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's prospectus supplement filed with the Securities and Exchange Commission on September 30, 2011. The Company's further development is highly dependent on future medical
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
2. NeoStem Announces Closing of Public Offering for $16,500,000 in Gross Proceeds
3. The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research
4. NeoStem to Present at Two Investor Events This Month
5. NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development
6. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
7. NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1
8. NeoStem Acquires Progenitor Cell Therapy
9. NeoStem Chairman and CEO to be Honored at the Moves 2010 Power Women Awards
10. NeoStem Presented at NASDAQ MarketSite in New York to Discuss Entry Into Merger Agreement With Progenitor Cell Therapy
11. FOX Business Network Airing In-Depth Look at NeoStem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 PlaqueTec ... Erfassung biologischer Daten in Verbindung mit Herzerkrankungen ... Das LBS nimmt gleichzeitig mehrere Blutproben von ... und sucht erhöhte biologische Aktivitäten in erkrankten ... Entdeckung und Entwicklung neuer Medikamente und Therapeutika ...
(Date:7/28/2014)... July 28, 2014 According to ... Market Research "Regenerative Medicine (Bone and Joint) Market ... Tissue Engineering; By Applications - Bone Graft Substitutes, ... - Global Industry Analysis, Size, Share, Growth, Trends ... medicine (bone and joint) market was valued at ...
(Date:7/28/2014)... 28, 2014  David Hardison, Ph.D., vice president ... , has been elected chairman of the board ... non-profit working to establish common protocols around the ... relates to electronic health records. ... collaborating with organizations across the research and health ...
(Date:7/28/2014)... Francisco, California (PRWEB) July 28, 2014 ... USD 604.40 billion by 2020, according to a new ... coupled with the rising demand for effective vaccines and ... patients with unmet medical needs is expected to drive ... the need to enhance agricultural productivity via the use ...
Breaking Biology Technology:PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4
... 20, 2010 A pediatrician, nurses, and staff from ... at Berlin Elementary School on Monday, December 20th to ... to the student,s family. Magellan Biosciences has donated test ... II analyzers, which provide three-minute blood-lead results from a ...
... Technologies, Inc., a leading provider of software and services ... upcoming Web seminars to help existing and potential new ... to qualify for valuable Meaningful Use incentive dollars. ... Avatar™ 2011 electronic health record (EHR) software recently achieved ...
... InterMune, Inc. (Nasdaq: ITMN ) today ... for the commercialization of Esbriet™ (pirfenidone) in Europe.  InterMune,s ... CHMP opinion that is now awaiting ratification by the ... Officer and President of InterMune, said, "We are very ...
Cached Biology Technology:Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students 2Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students 3Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students 4Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students 5Netsmart Technologies to Host Valuable Meaningful Use Web Seminars 2Netsmart Technologies to Host Valuable Meaningful Use Web Seminars 3Netsmart Technologies to Host Valuable Meaningful Use Web Seminars 4InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 2InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 3InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 4InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 5InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 6
(Date:7/28/2014)... years ago, MIT professor John Essigmann and colleagues from the ... drug. They thought if they could induce the virus to ... die out a strategy that our immune system uses ... drug, which caused HIV to mutate at an enhanced rate, ... patients in a small clinical trial reported in 2011. In ...
(Date:7/28/2014)... other forms of dementia, but the research community is ... Washington bioengineers have a designed a peptide structure that ... proteins into a state that,s linked to widespread diseases ... and Lou Gehrig,s disease. The synthetic molecule blocks these ... an abnormally folded form by targeting a toxic intermediate ...
(Date:7/28/2014)... Rice University researchers are using magnetic beads and ... can be used as microscale models for polymer macromolecules. ... introduced as theory in the 1950s, can be made ... be of interest to materials scientists who study the ... Rice chemical and biomolecular engineer Sibani Lisa Biswal and ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Seeing is bead-lieving 2
... Baltimore, MDStem cells are the body,s primal cells, retaining ... of cells over many cycles of cell division. How ... have identified a gene, named scrawny, that appears to ... stem cells in their undifferentiated state. Understanding how stem ...
... long suffered an identity crisis. Pop culture heedlessly ... dinosaurs. Even paleontologists assumed that because the creatures flew, they ... legs to take flight. Now comes ... 500 pounds of reptilian heft into flight required pterosaurs to ...
... have discovered a new way for bacteria to transfer ... raises the unsettling possibility that bacterial swapping of toxins ... previously imagined. , In a laboratory experiment, the scientists ... a notorious bacterium that causes toxic shock syndrome and ...
Cached Biology News:'Scrawny' gene keeps stem cells healthy 2Four, three, two, one . . . pterosaurs have lift off 2NYU scientists discover dangerous new method for bacterial toxin transfer 2NYU scientists discover dangerous new method for bacterial toxin transfer 3NYU scientists discover dangerous new method for bacterial toxin transfer 4
... evolutionarily conserved form of cell suicide, which ... central component of this process is a ... These enzymes participate in a series of ... pro-apoptotic signals and result in the cleavage ...
...
...
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
Biology Products: